Drug intelligence / Profile preview

DOS3w

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

DOS3w is a chemotherapy regimen consisting of docetaxel, oxaliplatin, and S-1, administered every third week. It has been evaluated as a first-line treatment for patients with advanced gastro-esophageal adenocarcinoma (aGEA) or non-resectable gastric cancer. The regimen aims to determine the maximum tolerated dose and evaluate its safety profile, response rate, progression-free survival, and overall survival.

Targets

DNATS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on DOS3w.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DOS3w.

Explore the full profile